US 11,896,644 B2
Inhibition of beta-arrestin oligomerization in tauopathy
Jung A. Woo, Wesley Chapel, FL (US); Stephen Bryant Liggett, Treasure Island, FL (US); David E. Kang, Wesley Chapel, FL (US); Yu Chen, Tampa, FL (US); and Eric Lewandowski, Tampa, FL (US)
Assigned to UNIVERSITY OF SOUTH FLORIDA, Tampa, FL (US)
Appl. No. 17/798,041
Filed by UNIVERSITY OF SOUTH FLORIDA, Tampa, FL (US)
PCT Filed Feb. 8, 2021, PCT No. PCT/US2021/017114
§ 371(c)(1), (2) Date Aug. 5, 2022,
PCT Pub. No. WO2021/159093, PCT Pub. Date Aug. 12, 2021.
Claims priority of provisional application 62/971,510, filed on Feb. 7, 2020.
Prior Publication US 2023/0116783 A1, Apr. 13, 2023
Int. Cl. A61K 38/17 (2006.01); A61P 25/28 (2006.01); A61K 31/42 (2006.01); A61K 31/437 (2006.01); A61K 31/496 (2006.01)
CPC A61K 38/1709 (2013.01) [A61K 31/42 (2013.01); A61K 31/437 (2013.01); A61K 31/496 (2013.01); A61P 25/28 (2018.01)] 7 Claims
OG exemplary drawing
 
1. A method of treating a tauopathy in a subject, the method comprising administering to the human subject a therapeutically effective amount of a β-arrestin oligomerization inhibitor, wherein the inhibitor is a compound having a structure or a pharmaceutically-acceptable salt thereof selected from the group consisting of:

OG Complex Work Unit Chemistry
wherein R1 is hydrogen or an alkyl group;
wherein Ar is an aryl group; and
wherein when R1 is an alkyl group, the stereochemistry at Ca is racemic, substantially R, or substantially S;

OG Complex Work Unit Chemistry
wherein Ar is an aryl group;

OG Complex Work Unit Chemistry
wherein R2 and R3 are, independently, hydrogen or an alkyl group; and Ar is an aryl group;

OG Complex Work Unit Chemistry
wherein Ar1 and Ar2 are, independently, an aryl group; and
wherein X is CH2 or C═O;

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
wherein Ar1 and Ar2 are, independently, an aryl group; and

OG Complex Work Unit Chemistry